Sectors
Health, BioTech
Headquarters
Menlo Park, CA, USA
CEO
Oguzhan Atay
BillionToOne shares, as of April 21, 2025, are valued at a price per share implying an approximate -5.9% relative to the most recent significant secondary market activity in September 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine BillionToOne's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for BillionToOne.
Register today to view the full report, with more in-depth details and analytics
Latest funding round
XXXXX
XX-XX-XXXX
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
BillionToOne generated $153.0M in revenue as of 2024, reflecting a year-over-year growth rate of +112.5%, according to PM Insights' market research.
BillionToOne shares, as of April 21, 2025, are valued at a price per share implying an approximate -5.9% relative to the most recent significant secondary market activity in September 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine BillionToOne's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for BillionToOne.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
